GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-04-16| Asia-PacificR&D

ROSALIND Partners with Two Korean Biotechs to Expand Cancer Research in Asia

by Tyler Chen
Share To

US-based bioinformatics company, ROSALIND, formerly known as OnRamp BioInformatics, announced a partnership with two Korea-based biotech companies, Geninus and HELiXrUS, to provide a single cell data analysis solution to cancer researchers in Asia. 

Geninus, a spin-off of Samsung Genome Institute, focuses on cancer precision medicine. HELiXrUS Inc. is a digital healthcare and multi-omics biotech based in Seoul.

 

Direct Measurement of Gene Expression at Single Cell Resolution

Geninus intends to merge ROSALIND’s platform with its single cell RNA sequencing solution to further interpret the data and synchronize them with labs across the globe. The combined product would be able to directly measure gene expression and genetic alteration at scale with single cell resolution to quantify intracellular heterogeneity and characterize cell types, states, and cellular transition dynamics. It can support analysis on single cell gene expression, single cell immune profiling, single nucleus gene expression, single cell multiome ATAC, and spatial gene expression. 

“The ROSALIND Single Cell Solution enables the rapid processing of data sets and provides scientists a best-in-class experience for annotating cell clusters and performing comparisons to explore their biology,” said Dr. Woong-Yang Park, CEO of Geninus. “Additionally, this powerful platform allows us to seamlessly share and collaborate with our customers, creating an interactive and engaging experience for both them and us.”

Founded in 2018, Geninus already has 16 patents and 165 scientific publications under its belt. Besides, it has partnered with 34 local and overseas companies and has snagged approximately 14 million in investment.

 

Delivering Data Analysis Solution to Prospective Clients

HELiXrUS, the third party in this collaboration, will streamline and provide local support service of the bioinformatics solution to prospective clients. They include clinicians, academic researchers, and pharmaceutical companies who work on translational life sciences or cancer-related topics in South Korea or other Asian markets.

Related Article: Korea Made Humira Biosimilar Begins Sales in Australia, Marks its Presence in Third Overseas Market

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Key Market Trends Shaping Health Systems and Specialty Pharmacies
2025-01-08
Core8 Group and MedArmor to Pioneer Vietnam’s First AI x ESG Hospital
2024-12-10
Biotech on the Ballot: How the U.S. Presidential Election Puts Industry Policy to the Test
2024-11-06
LATEST
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top